Skip to main content
Atrás
EXAS logo

Exact Sciences Corporation

Calidad de datos: 100%
Sobrecompra
EXAS
NASDAQ Healthcare Medical - Diagnostics & Research
$104.91
$0.00 (0.00%)
Cap. Mercado: 20.03B
Rango del Día
$104.90 $104.98
Rango de 52 Semanas
$38.81 $104.98
Volumen
21,562,141
Promedio 50D / 200D
$103.02 / $74.29
Cierre Anterior
$104.91

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -96.3 0.3
P/B 8.3 2.9
ROE % -8.7 3.7
Net Margin % -6.4 3.8
Rev Growth 5Y % 16.4 10.0
D/E 1.1 0.2

Precio Objetivo de Analistas

Hold
$103.18 -1.6%
Low: $85.00 High: $105.00
P/E Futuro
582.8
EPS Futuro
$0.18
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
3.7 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $3.13
$2.82 – $3.28
5.1 B 1
FY2029 $2.09
$1.88 – $2.18
4.9 B 1
FY2028 $1.74
$0.94 – $2.41
4.6 B 5

Puntos Clave

Revenue grew 16.43% annually over 5 years — strong growth
Generating 356.78M in free cash flow
Capital efficient — spends only 4.15% of revenue on capex

Crecimiento

Revenue Growth (5Y)
16.43%
Revenue (1Y)17.69%
Earnings (1Y)N/A
FCF Growth (3Y)234.28%

Calidad

Return on Equity
-8.66%
ROIC-1.51%
Net Margin-6.40%
Op. Margin-3.05%

Seguridad

Debt / Equity
1.05
Current Ratio2.43
Interest Coverage-3.01

Valoración

P/E Ratio
-96.30
P/B Ratio8.34
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17.69% Revenue Growth (3Y) 13.97%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 16.43% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.25B Net Income (TTM) -207.95M
ROE -8.66% ROA -3.55%
Gross Margin 69.69% Operating Margin -3.05%
Net Margin -6.40% Free Cash Flow (TTM) 356.78M
ROIC -1.51% FCF Growth (3Y) 234.28%
Safety
Debt / Equity 1.05 Current Ratio 2.43
Interest Coverage -3.01 Dividend Yield 0.00%
Valuation
P/E Ratio -96.30 P/B Ratio 8.34
P/S Ratio 6.17 PEG Ratio 1.15
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 20.03B Enterprise Value 21.59B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.25B 2.76B 2.50B 2.08B 1.77B
Net Income -207.95M -1.03B -204.15M -623.51M -595.63M
EPS (Diluted) -1.10 -5.59 -1.13 -3.54 -3.48
Gross Profit 2.26B 1.92B 1.76B 1.42B 1.31B
Operating Income -99.08M -1.05B -215.01M -593.51M -855.68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.86B 5.93B 6.47B 6.23B 6.68B
Total Liabilities 3.46B 3.53B 3.33B 3.18B 3.30B
Shareholders' Equity 2.40B 2.40B 3.15B 3.04B 3.39B
Total Debt 2.52B 2.75B 2.55B 2.45B 2.38B
Cash & Equivalents 956.00M 600.89M 605.38M 242.49M 315.47M
Current Assets 1.56B 1.57B 1.19B 982.26M 1.43B
Current Liabilities 641.15M 732.19M 514.70M 412.75M 517.07M